Skip to main content
Fig. 1 | Trials

Fig. 1

From: Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients—a randomized rater-blinded trial

Fig. 1

The eligible participants (ITT (intention-to-treat) population) in the BDNF trial, recruited from the five university hospitals, will undergo testing for their BDNF CpG -87 methylation status. Baseline characteristics, including measures such as the Hamilton Depression Rating Scale (HDRS-24) and Montgomery–Åsberg Depression Rating Scale (MADRS) score, will also be collected. Subsequently, participants will be randomly assigned to one of two treatment arms: a the Marker group, where test results will be communicated to both participants and treating physicians, and the marker status will be considered in treatment decisions, or b TAU (treatment-as-usual) group, where no information about the test result will be provided to participants or physicians, and treatment decisions will be based on the national guidelines [1]

Back to article page

Trials

ISSN: 1745-6215